NovoCure
NVCR
63 hedge funds and large institutions have $162M invested in NovoCure in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 11 closing their positions.
417% more call options, than puts
Call options by funds: $2.43M | Put options by funds: $470K
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
5% less funds holding
Funds holding: 66 → 63 (-3)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
29% less capital invested
Capital invested by funds: $227M → $162M (-$65.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$7.07M |
| 2 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
+$4.56M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.32M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$1.43M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$766K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.1M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$7.11M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.07M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$694K |
| 5 |
Flossbach Von Storch
Cologne,
Germany
|
-$395K |
NVCR Hedge Fund Activity: Q3 2016 in Review
63 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2016, worth a combined $162M — down 29% from $227M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NVCR and 9 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 27 added.
The largest buyer was Tamarack Advisers, opening a new position worth an estimated $7.07M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $30.1M sold.
- 63 institutional investors held NovoCure (NVCR) as of Q3 2016, down from 66 in Q2 2016.
- Funds reported $162M of NovoCure stock for Q3 2016, down 29% quarter-over-quarter.
- 9 funds opened new NovoCure positions in Q3 2016 and 11 closed out, a net change of -2 holders.
- The largest NovoCure buyer in Q3 2016 was Tamarack Advisers, an estimated $7.07M added.
- The largest NovoCure seller in Q3 2016 was T. Rowe Price Associates, an estimated $30.1M sold.
Based on aggregated 13F filings for Q3 2016.